Kisspeptin and GPR54 Receptor Expression in Endometrial Cancer Tissue.
AMH
AMHRII
GPR54
KISS
endometrial cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Feb 2023
15 Feb 2023
Historique:
received:
07
12
2022
revised:
27
01
2023
accepted:
11
02
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
Kisspeptin (KISS) is a natural peptide-discovered in 1996 as a factor inhibiting the ability to metastasize in malignant melanoma. This protein plays also a regulatory role in the process of puberty, the menstrual cycle, spermatogenesis, implantation and development of the human placenta. The present study aimed to evaluate the expression of KISS and its receptor GPR54 in endometrial cancer (EC) tissue, depending on the histological type of cancer, its stage, various demographic characteristics, and clinical conditions in 214 hysterectomy patients. Expression of KISS and GPR54 was confirmed in 99.5% and 100% of the cases, respectively. Hormone replacement therapy and the coexistence of the anti-Müllerian type 2 receptor in cancer tissue enhanced KISS expression. Smoking, on the other hand, decreased KISS expression. GPR54 expression increased with the advancement of the disease (according to FIGO classification). Also, the presence of the anti-Müllerian type 2 receptor in EC increased the level of GPR54. Hypertension, age and miscarriage harmed the presence of GPR54. The histological type of cancer, diabetes type 2, body mass index, hormonal contraception, number of deliveries, birth weight of newborns, breastfeeding time, and the presence of AMH in EC tissue were not associated with the expression of either KISS nor GPR54. The KISS level was also significantly related to the GPR54 level. Considering that KISS is a non-toxic peptide with antimetastatic properties, further investigation is essential to determine the clinical significance of this peptide.
Identifiants
pubmed: 36831570
pii: cancers15041228
doi: 10.3390/cancers15041228
pmc: PMC9954558
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : National Science Center
ID : 2021/05/X/NZ4/01236
Références
Clin Exp Pharmacol Physiol. 2019 Jul;46(7):625-634
pubmed: 30932210
Am J Pathol. 2003 Feb;162(2):609-17
pubmed: 12547718
Hum Reprod Update. 2019 May 1;25(3):326-343
pubmed: 30649364
J Assist Reprod Genet. 2016 Apr;33(4):535-43
pubmed: 26879207
Ann Clin Biochem. 2014 Jan;51(Pt 1):89-96
pubmed: 23869023
Anticancer Res. 2007 Jul-Aug;27(4B):2499-504
pubmed: 17695545
Eur J Cancer. 2007 Jun;43(9):1452-9
pubmed: 17442564
Front Physiol. 2018 Mar 13;9:209
pubmed: 29593567
J BUON. 2018 May-Jun;23(3):598-603
pubmed: 30003725
Cells. 2020 Oct 17;9(10):
pubmed: 33080800
J Neurosci. 2009 Sep 23;29(38):11859-66
pubmed: 19776272
Reprod Biol Endocrinol. 2019 Aug 9;17(1):65
pubmed: 31399145
Mol Med Rep. 2017 Nov;16(5):7585-7590
pubmed: 28944853
Nat Rev Endocrinol. 2020 Aug;16(8):407-420
pubmed: 32427949
Andrologia. 2019 Nov;51(10):e13409
pubmed: 31502328
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8161-8173
pubmed: 31966668
Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:261-266
pubmed: 31344665
Front Endocrinol (Lausanne). 2018 Mar 27;9:115
pubmed: 29662466
J Endocrinol. 2016 Jun;229(3):R83-98
pubmed: 27340201
Int J Endocrinol Metab. 2017 Apr 22;15(3):e44337
pubmed: 29201072
Hum Reprod. 2012 Dec;27(12):3552-9
pubmed: 22956346
PLoS One. 2011 Feb 09;6(2):e14671
pubmed: 21347414
Ann Endocrinol (Paris). 2010 May;71(3):198-200
pubmed: 20362959
Eur J Cancer. 2019 Jul;115:68-78
pubmed: 31121525
Int J Gynecol Cancer. 2014 Feb;24(2):210-7
pubmed: 24407584
Dis Markers. 2019 Oct 20;2019:5603474
pubmed: 31772690
Trends Endocrinol Metab. 2009 Jul;20(5):237-42
pubmed: 19541497
Med Mol Morphol. 2015 Jun;48(2):76-84
pubmed: 24908069
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2091-2099
pubmed: 28368443
Prenat Diagn. 2008 Apr;28(4):299-303
pubmed: 18317999
Clin Endocrinol (Oxf). 2012 Jun;76(6):887-93
pubmed: 22168508
J Clin Invest. 2020 Dec 1;130(12):6739-6753
pubmed: 33196464
J Neuroendocrinol. 2011 Jan;23(1):52-64
pubmed: 21029216
Am J Reprod Immunol. 2012 Feb;67(2):132-9
pubmed: 21996032
Int J Cancer. 2004 Oct 10;111(6):868-72
pubmed: 15300798
J Endocrinol. 2015 Nov;227(2):105-15
pubmed: 26446276
Endocr Res. 2012;37(2):78-88
pubmed: 22489921
Pregnancy Hypertens. 2016 Jan;6(1):79-87
pubmed: 26955777
Prenat Diagn. 2009 Oct;29(10):982-5
pubmed: 19582702
Nutr Metab Cardiovasc Dis. 2020 Jun 9;30(6):889-895
pubmed: 32409274
Int J Mol Med. 2013 Oct;32(4):747-54
pubmed: 23969598
PLoS One. 2011;6(6):e21599
pubmed: 21738726
Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:110-5
pubmed: 26918694
J Clin Endocrinol Metab. 2005 Dec;90(12):6609-15
pubmed: 16174713
Reprod Biol Endocrinol. 2022 May 23;20(1):81
pubmed: 35606759
Mol Cancer Ther. 2011 Apr;10(4):580-90
pubmed: 21282360
Nature. 2001 May 31;411(6837):613-7
pubmed: 11385580
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10216-E10223
pubmed: 29109258
J Am Heart Assoc. 2017 Apr 14;6(4):
pubmed: 28411243
Laryngoscope. 2014 May;124(5):E167-74
pubmed: 24254791
Clin Cancer Res. 2004 Feb 15;10(4):1379-83
pubmed: 14977840
Endocrinology. 2006 May;147(5):2122-6
pubmed: 16469799
Neuroendocrinology. 2014;99(1):18-32
pubmed: 24008670
Endocrinology. 2012 Nov;153(11):5130-6
pubmed: 23015291
Exp Ther Med. 2021 Sep;22(3):1019
pubmed: 34373705
Front Endocrinol (Lausanne). 2018 Aug 03;9:437
pubmed: 30123188
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Endocrinology. 2007 Dec;148(12):5752-60
pubmed: 17823266
Blood Press Monit. 2015 Jun;20(3):144-9
pubmed: 25647283
Curr Opin Pharmacol. 2022 Dec;67:102319
pubmed: 36413854
J Clin Endocrinol Metab. 2012 Aug;97(8):E1458-67
pubmed: 22577171
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30884769
Biochem Biophys Res Commun. 2001 Sep 7;286(5):958-63
pubmed: 11527393